Latest News and Press Releases

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax

Remedy Plan Therapeutics Showcases at 2024 ASH Annual Meeting, Synergy Between RPT1G and Venetoclax

Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myelomonocytic Leukaemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Chronic...

Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.Global insights into the...

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...

Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients

Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...

Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Market by Type, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been...

-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion- BERKELEY HEIGHTS,...